O8Z Stock Overview
Develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sonoma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.09 |
| 52 Week High | US$7.51 |
| 52 Week Low | US$2.60 |
| Beta | 1.38 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -71.20% |
| 33 Year Change | -96.48% |
| 5 Year Change | -96.07% |
| Change since IPO | -99.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| O8Z | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.2% | 1.1% |
| 1Y | -71.2% | -15.2% | 10.7% |
Return vs Industry: O8Z underperformed the German Pharmaceuticals industry which returned -15.2% over the past year.
Return vs Market: O8Z underperformed the German Market which returned 10.7% over the past year.
Price Volatility
| O8Z volatility | |
|---|---|
| O8Z Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: O8Z's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine O8Z's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10 | Amy Trombly | sonomapharma.com |
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye and nasal care, oral care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. The company offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis; and Pediacyn, an atopic dermatitis hydrogel. It also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product.
Sonoma Pharmaceuticals, Inc. Fundamentals Summary
| O8Z fundamental statistics | |
|---|---|
| Market cap | €2.97m |
| Earnings (TTM) | -€4.10m |
| Revenue (TTM) | €11.41m |
0.3x
P/S Ratio-0.7x
P/E RatioIs O8Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| O8Z income statement (TTM) | |
|---|---|
| Revenue | US$12.70m |
| Cost of Revenue | US$7.85m |
| Gross Profit | US$4.85m |
| Other Expenses | US$9.41m |
| Earnings | -US$4.56m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.45 |
| Gross Margin | 38.17% |
| Net Profit Margin | -35.91% |
| Debt/Equity Ratio | 4.1% |
How did O8Z perform over the long term?
See historical performance and comparison